必须声明标量变量 "@Script_ID"。 新型冠状病毒肺炎(COVID-19)药物防治研究进展-《赣南医学院学报》

[1]谢保平,谢景春,赵玥,等.新型冠状病毒肺炎(COVID-19)药物防治研究进展[J].赣南医学院学报,2020,40(02):1.
 XIE Bao-ping,XIE Jing-chun,ZHAO Yue,et al.Pharmaceuticals research progress on prevention and treatment of COVID-19[J].,2020,40(02):1.
点击复制

新型冠状病毒肺炎(COVID-19)药物防治研究进展()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
40
期数:
2020年02期
页码:
1
栏目:
新型冠状病毒专题
出版日期:
2020-03-18

文章信息/Info

Title:
Pharmaceuticals research progress on prevention and treatment of COVID-19
作者:
谢保平1谢景春2赵玥3程禄萍3廖晓飞4陈治希3
 (1.赣南医学院心脑血管疾病防治教育部重点实验室;2.于都县人民医院;3.赣南医学院药学院;4.赣州市人民医院,江西 赣州341000)
Author(s):
XIE Bao-ping1 XIE Jing-chun2 ZHAO Yue3 CHEN Lu-ping3 LIAO Xiao-fei4 CHEN Zhi-xi3
(1.Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University; 2.The People’s Hospital of Yudu County, Ganzhou Jiangxi , 3.College of Pharmacy, Gannan Medical University; 4.The People’s Hospital of Ganzhou City, Ganzhou, Jiangxi 341000)
关键词:
新型冠状病毒肺炎抗病毒药物免疫抑制剂中药生物制剂研究进展
Keywords:
COVID-19 antiviral drug immunosuppressant Chinese materia medica biological agent Research progress
分类号:
R511
文献标志码:
A
摘要:
新型冠状病毒肺炎 (COVID-19)是一种新型冠状病毒感染的肺炎,伴有发热、咳嗽、呼吸困难、低氧血症、脓毒症休克、代谢性酸中毒和出凝血功能障碍等症状。目前治疗尚无特效手段,中西医结合的药物治疗是最主要的治疗手段。本文综述了COVID-19药物治疗的研究进展,并提出相关药物可能的作用机制,为抗COVID-19新药和疫苗研发提供指导。
Abstract:
COVID-19 is a new type of coronavirusinfected pneumonia, accompanied by fever, cough, dyspnea, hypoxemia, sepsis shock, metabolic acidosis, and coagulation dysfunction. At present, there are no special treatments, and the combination of traditional Chinese medicine and western medicine is the main treatment approach. This article reviews the research progress of COVID-19 drug therapy, and proposes possible mechanisms of action of related pharmaceuticals, providing guidance for the development of new antiCOVID-19 pharmaceuticals and vaccines.

参考文献/References:

[1]CHAN JF, KOK KH, ZHU Z, et al. Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 2020, 9: 221-236.
[2]ZHU N, ZHANG D, WANG W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. N Engl J Med, 2020,382(8):727-733.
[3]ZUMLA A, CHAN JF, AZHAR EI, et al.Coronavirusesdrug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016,15(5):327-347.
[4]ZHOU YS, YANG Y, HUANG JW, et al. Advances in MERSCoV Vaccines and Therapeutics Based on the ReceptorBinding Domain[J]. Viruses,2019,11(1):60.
[5]DONG N, YANG X, YE L, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China[J]. bioRxiv, 2020. doi:https://doi.org/10.1101/2020.01.20.913368.
[6]RICHARDSON P, GRIFFIN I, TUCKER C, et al. Baricitinib as potential treatment for 2019nCoV acute respiratory disease[J]. Lancet, 2020, 395(10223): e30-e31.
[7]HOLSHUE ML, DEBOLT C, LINDQUIST S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020. doi:10.1056/NEJMoa2001191.
[8]WANG ML , CAO RY, ZHANG LK, et al. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus(2019nCoV) in Vitro[J]. Cell Res,2020. doi:10.1038/s41422-020-0282-0.
[9]国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-24]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf
[10]LIN S, SHEN RN, HE JD, et al. Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases[J/OL]. bioRxiv,2020.[2020-02-26].https://doi.org/10.1101/2020.01.31.929695.
[11]REBELLO KM, ANDRADENETO VV, ZUMA AA, et al. Lopinavir, an HIV1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes[J]. Parasitology, 2018,145(10): 1304-1310.
[12]BRITES C, NBREGA I, LUZ E, et al. Raltegravir versus lopinavir/ritonavir for treatment of HIVinfected latepresenting pregnant women[J]. HIV Clin Trials, 2018,19(3):94-100.
[13]邓卫宁,王利娜,崔艳丽.抗新型冠状病毒肺炎药物靶点的研究进展[J/OL].现代药物与临床:1-4[2020-02-26]. http://kns.cnki.net/kcms/detail/12.1407.R.20200226.1525.002.html.
[14]王先堃,孙娜,陈志海.法匹拉韦抗病毒治疗研究进展[J].中国新药杂志,2019,28(15):1824-1827.
[15]ZENG J, WANG H, XIE X, et al. Ribavirinresistant variants of footandmouth disease virus: the effect of restricted quasispecies diversity on viral virulence[J]. J Virol, 2014,88(8):4008-4020.
[16]JU J Y, KUMAR S, LI X X, et al. Nucleotide analogues as inhibitors of viral polymerases[J/OL]. bioRxiv, 2020.[2020-02-26].https://www.biorxiv.org/content/10.1101/2020.01.30.927574v1.abstract
[17]VINCENT MJ, BERGERON E, BENJANNET S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virol J, 2005,22(2):69.
[18]HULSEBERG CE, FNANT L, SZYMANSKADE WIJS K M, et al. Arbidol and other Low Molecular Weight Drugs That Inhibit Lassa and Ebola Viruses[J]. J Virol, 2019, 93(8): e02185-18.
[19]国家卫生健康委员会新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-02-26].http://www.nhc.gov.cn/yzygj/s7652m/202002/e84bd30142ab4d8982326326e4db22ea.shtml.
[20]邹璐,喻晓,吴雨沁,等.中医药防治重症新型冠状病毒肺炎的分析和思考[J/OL].上海中医药大学学报:1-6[2020-02-26]. https://doi.org/10.16306/j.1008-861x.2020.02.002.[21]王玉光,齐文升,马家驹,等.新型冠状病毒(2019-nCoV)肺炎中医临床特征与辨证治疗初探[J/OL].中医杂志:1-6[2020-02-26]. http://kns.cnki.net/kcms/detail/11.2166.R.20200129.1258.002.html.
[22]石岩,郜贺,赵亮,白长川.新型冠状病毒(2019-nCoV)感染的肺炎与风寒湿疫[J/OL].中华中医药学刊:1-7[2020-02-26]. http://kns.cnki.net/kcms/detail/21.1546.R.20200211.0907.002.html.
[23]韩园园,赵梦冉,石垚,等.中西医结合治疗新型冠状病毒肺炎的应用分析[J/OL].中草药:1-5[2020-02-26]. http://kns.cnki.net/kcms/detail/12.1108.R.20200218.1652.010.html.[24]姚开涛,刘明瑜,李欣,等.中药连花清瘟治疗新型冠状病毒感染的肺炎回顾性临床分析[J/OL].中国实验方剂学杂志:1-7[2020-02-26].https://doi.org/10.13422/j.cnki.syfjx.20201099.
[25]广东省药品监督管理局,广东省卫生健康委员会,广东省中医药局. 《广东省药品监督管理局,广东省卫生健康委员会,广东省中医药局关于透解祛瘟颗粒(曾用名“肺炎1号方”)临床使用有关规定的通知》[EB/OL].[2020-02-26]. http://mpa.gd.gov.cn/xwdt/tzgg/content/post_2888221.html.
[26]ZHANG DH, WU KL, ZHANG X, et al. In silico screening of chinese herbal medicines with the potential to derectly inhibit 2019 novel coronavirus[J]. Journal of Integrative Medicine, 2020. https://doi.org/10.1016/j.joim.2020.02.005.
[27]吴昊,王佳琪,杨雨薇,等.基于网络药理学和分子对接技术初步探索“清肺排毒汤”抗新型冠状病毒肺炎作用机制[J/OL].药学学报:1-18[2020-02-26]. https://doi.org/10.16438/j.0513-4870.2020-0136.
[28]张晋,宋昌梅,杲春阳,等.中药香囊辟瘟囊预防新型冠状病毒肺炎应用探讨[J/OL].北京中医药:1-7[2020-02-26]. http://kns.cnki.net/kcms/detail/11.5635.R.20200218.1047.002.html.
[29]徐艺.血必净在重症肺炎治疗中的效果观察[J].中国当代医药,2011,18(25):50-51.
[30]李洁.痰热清注射液治疗重症肺炎痰热壅肺证临床疗效观察[J].辽宁中医药大学学报,2013,15(3):182-184.
[31]王冬音.穿心莲内酯抑制肠道病毒D68复制的作用机制研究[D].长春:吉林大学, 2019.
[32]杜斌,邱海波,詹曦,等.新型冠状病毒肺炎药物治疗的思考[J].中华结核和呼吸杂志, 2020,43.DOI: 10.3760/cma.j.issn.1001-0939.2020.0012.
[33]陈岷,童荣生,边原,等.皮下注射α干扰素治疗2019年新型冠状病毒的循证快速评估[J/OL].医药导报:1-19[2020-02-26].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.
[34]杨宝峰,陈建国,魏敏杰,等.药理学[M].北京:人民卫生出版社,2018.
[35]罗伟,魏茂刚,魏海龙,等.重症新型冠状病毒肺炎合并糖皮质激素诱导糖尿病一例及糖皮质激素使用初探[J/OL].中国呼吸与危重监护杂志:1-5[2020-02-26]. http://kns.cnki.net/kcms/detail/51.1631.R.20200212.1727.002.html.
[36]冯缤,陈正贤,金龙伟,等.CoVID-19的临床特征及药物治疗思考[J/OL].今日药学:1-5[2020-02-26]. http://kns.cnki.net/kcms/detail/44.1650.R.20200225.1249.002.html.[37]CHENG Y, WONG R, SOO YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong[J]. Eur J Clin Microbiol Infect Dis, 2005, 24: 44-46.

相似文献/References:

[1]廖志文,周建荣,许才生,等.1例新型冠状病毒肺炎确诊过程的思考[J].赣南医学院学报,2020,40(02):1.
 LIAO Zhi-wen,ZHOU Jian-rong,Xu Cai-sheng,et al.Thinking on the diagnostic process of one case of novel coronavirus pneumonia[J].,2020,40(02):1.
[2]谢保平,谢景春,赵 玥,等.新型冠状病毒肺炎(COVID-19)药物防治研究进展[J].赣南医学院学报,2020,40(02):119.[doi:10.3969/j.issn.1001-5779.2020.02.003]
 XIE Bao-ping,XIE Jing-chun,ZHAO Yue,et al.Pharmaceuticals research progress on prevention and treatment of COVID-19[J].,2020,40(02):119.[doi:10.3969/j.issn.1001-5779.2020.02.003]
[3]廖志文,周建荣,许才生,等.1例新型冠状病毒肺炎确诊过程的思考[J].赣南医学院学报,2020,40(02):136.[doi:10.3969/j.issn.1001-5779.2020.02.007]
 LIAO Zhi-wen,ZHOU Jian-rong,XU Cai-sheng,et al.Thinking on the diagnostic process of one case of novel coronavirus pneumonia[J].,2020,40(02):136.[doi:10.3969/j.issn.1001-5779.2020.02.007]
[4]廖柄清,曾欢,彭凤,等.新型冠状病毒肺炎(COVID-19)合并急性肾损伤一例[J].赣南医学院学报,2020,40(03):1.
[5]唐杨,刘明山,林唐唐,等.中西医结合治疗新型冠状病毒肺炎案例三则[J].赣南医学院学报,2020,40(03):1.
 TANG Yang,LIU Ming-shan,LIN Tang-tang,et al.Analysis on the treatment of the three COVID-2019 cases with the combination of traditional Chinese and western medicine[J].,2020,40(02):1.
[6]廖柄清,曾 欢,彭 凤,等.新型冠状病毒肺炎(COVID-19)合并急性肾损伤一例[J].赣南医学院学报,2020,40(03):243.[doi:10.3969/j.issn.1001-5779.2020.03.006]
[7]唐 杨,刘明山,林唐唐,等.中西医结合治疗新型冠状病毒肺炎案例三则[J].赣南医学院学报,2020,40(03):249.[doi:10.3969/j.issn.1001-5779.2020.03.008]
 TANG Yang,LIU Ming-shan,LIN Tang-tang,et al.Analysis on the treatment of the three COVID-19 cases with the combination of traditional Chinese and western medicine[J].,2020,40(02):249.[doi:10.3969/j.issn.1001-5779.2020.03.008]
[8]朱林,郭飞,王玲玲.新型冠状病毒肺炎老年患者的临床及影像特征分析[J].赣南医学院学报,2020,40(预出版):1.
 ZHU Lin,GUO Fei,WANG Ling ling.Analysis of clinical and imaging features of elderly patients with COVID-19’ s elderly patients[J].,2020,40(02):1.
[9]郭林,袁小亮,陈懿建,等.1例危重症型新型冠状病毒肺炎的诊疗分析及建议[J].赣南医学院学报,2020,40(预出版):1.
 GUO Lin,YUAN Xiao-liang,CHEN Yi-jian,et al.Diagnosis and Treatment of One Severe Case with COVID-19: Analysis and Suggestions[J].,2020,40(02):1.
[10]王芬,胡美玉,黎琪,等.1例危重型新冠肺炎合并肺心病患者的护理[J].赣南医学院学报,2020,40(预出版):1.

备注/Memo

备注/Memo:
 作者简介:谢保平,男,硕士,助理实验师,研究方向:中药防治老年病机制研究。E-mail:m18932446096_1@163.com  
 通信作者:陈治希,男,硕士,讲师,研究方向:药物合成与机制研究。E-mail:czxb22@163.com
更新日期/Last Update: 2020-03-06